SI1355942T1 - Glp-1 fuzijski proteini - Google Patents

Glp-1 fuzijski proteini

Info

Publication number
SI1355942T1
SI1355942T1 SI200130878T SI200130878T SI1355942T1 SI 1355942 T1 SI1355942 T1 SI 1355942T1 SI 200130878 T SI200130878 T SI 200130878T SI 200130878 T SI200130878 T SI 200130878T SI 1355942 T1 SI1355942 T1 SI 1355942T1
Authority
SI
Slovenia
Prior art keywords
fusion proteins
glp
proteins
glucagon
peptides
Prior art date
Application number
SI200130878T
Other languages
English (en)
Inventor
Wolfgang Glaesner
Radmilla Micanovic
Sheng-Hung Rainbow Tschang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22954069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1355942(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SI1355942T1 publication Critical patent/SI1355942T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
SI200130878T 2000-12-07 2001-11-29 Glp-1 fuzijski proteini SI1355942T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25195400P 2000-12-07 2000-12-07
PCT/US2001/043165 WO2002046227A2 (en) 2000-12-07 2001-11-29 Glp-1 fusion proteins
EP01995845A EP1355942B1 (en) 2000-12-07 2001-11-29 Glp-1 fusion proteins

Publications (1)

Publication Number Publication Date
SI1355942T1 true SI1355942T1 (sl) 2009-02-28

Family

ID=22954069

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200130878T SI1355942T1 (sl) 2000-12-07 2001-11-29 Glp-1 fuzijski proteini
SI200130945T SI1724284T1 (sl) 2000-12-07 2001-11-29 Glp-1 fuzijski proteini

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200130945T SI1724284T1 (sl) 2000-12-07 2001-11-29 Glp-1 fuzijski proteini

Country Status (30)

Country Link
US (1) US7271149B2 (sl)
EP (2) EP1724284B1 (sl)
JP (2) JP2004528014A (sl)
KR (2) KR20080085082A (sl)
CN (2) CN1483041A (sl)
AT (2) ATE437891T1 (sl)
AU (2) AU2002226897B2 (sl)
BR (1) BR0116024A (sl)
CA (2) CA2716959A1 (sl)
CY (2) CY1108485T1 (sl)
CZ (2) CZ308214B6 (sl)
DE (2) DE60139430D1 (sl)
DK (2) DK1355942T3 (sl)
EA (1) EA005584B1 (sl)
EC (1) ECSP064643A (sl)
ES (2) ES2311560T3 (sl)
HK (1) HK1061411A1 (sl)
HR (1) HRP20030455A2 (sl)
HU (2) HU229218B1 (sl)
IL (3) IL155812A0 (sl)
MX (1) MXPA03005036A (sl)
NO (3) NO331273B1 (sl)
NZ (1) NZ525577A (sl)
PL (2) PL393178A1 (sl)
PT (2) PT1355942E (sl)
SI (2) SI1355942T1 (sl)
SK (2) SK288088B6 (sl)
UA (2) UA93662C2 (sl)
WO (1) WO2002046227A2 (sl)
ZA (1) ZA200303642B (sl)

Families Citing this family (326)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
JP2003530852A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
HU229208B1 (en) * 2000-06-16 2013-09-30 Lilly Co Eli Glucagon-like peptide-1 analogs
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060057651A1 (en) 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
EP1341902A2 (en) 2000-12-08 2003-09-10 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
US7199217B2 (en) * 2000-12-13 2007-04-03 Eli Lilly And Company Amidated glucagon-like peptide-1
CA2455963C (en) * 2001-07-31 2017-07-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1, exendin-4, peptide analogs and uses thereof
US7101843B2 (en) * 2001-08-23 2006-09-05 Eli Lilly And Company Glucagon-like peptide-1 analogs
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
CN1630709A (zh) * 2001-10-18 2005-06-22 百时美施贵宝公司 人胰高血糖素样多肽－1模拟物和它们在治疗糖尿病和相关状况中的应用
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
JP4282485B2 (ja) * 2002-01-08 2009-06-24 イーライ リリー アンド カンパニー 伸長グルカゴン様ペプチド−１アナログ
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
DE60331226D1 (de) * 2002-05-24 2010-03-25 Medtronic Inc Verfahren und dna-konstrukte zur produktion von polypeptiden mit hoher ausbeute
JP2006504406A (ja) * 2002-06-28 2006-02-09 セントカー・インコーポレーテツド 哺乳動物のｃｈ１欠失ミメティボディ、組成物、方法および使用
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CN1713920A (zh) * 2002-08-30 2005-12-28 比奥雷克西斯药物公司 被修饰的转铁蛋白融合蛋白
AU2003283216A1 (en) * 2002-12-03 2004-06-23 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
EP1688148A1 (en) * 2002-12-03 2006-08-09 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
KR20050086948A (ko) 2002-12-27 2005-08-30 디오벡스, 인코포레이티드 인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
EP1582223A4 (en) * 2003-01-10 2007-01-17 Niigata Tlo Corp VECTOR FOR GENE THERAPY AND METHOD FOR THE QUANTIFICATION OF A TARGET PROTEIN IN MAMMALIAN OR CULTURAL CELLS BY APPLYING THE VECTOR FOR GENE THERAPY
US20070059376A1 (en) * 2003-02-06 2007-03-15 Shinji Takeoka Peptide conjugate
MXPA05009940A (es) * 2003-03-19 2005-12-05 Lilly Co Eli Compuestos de glp-1 de enlace de glicol polietilenico.
KR101198346B1 (ko) 2003-04-08 2012-11-06 노보 노르디스크 에이/에스 크로마토그래피 고정상의 재생
WO2004089985A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
ATE549028T1 (de) 2003-05-15 2012-03-15 Tufts College Stabile analoga von glp-1
EP2368909A1 (en) * 2003-06-12 2011-09-28 Eli Lilly and Company GLP-1 analog fusion proteins
ES2298785T3 (es) * 2003-06-12 2008-05-16 Eli Lilly And Company Proteinas de fusion.
EP1667724A2 (en) * 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
SI2932981T1 (sl) * 2003-09-19 2021-11-30 Novo Nordisk A/S Albumin-vezavni derivati GLP-1
US20090238838A1 (en) * 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
KR101135244B1 (ko) * 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
RU2352583C2 (ru) 2003-11-13 2009-04-20 Ханми Фарм. Инд. Ко., Лтд. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
EP1694356B1 (en) 2003-12-09 2011-02-16 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
EP1696962A2 (en) * 2003-12-18 2006-09-06 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
US20060252693A1 (en) * 2004-01-29 2006-11-09 Wolfgang Glaesner Glucagon-like peptide-1 analogs
CN1980687B (zh) * 2004-02-09 2015-05-13 人类基因科学公司 清蛋白融合蛋白
SI1729795T1 (sl) * 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albuminski fuzijski proteini
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CA2849552A1 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
EP2335716A3 (en) 2004-02-11 2011-10-19 Amylin Pharmaceuticals Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
CA2563379A1 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
DK2348114T3 (en) 2004-04-21 2018-09-03 Alexion Pharma Inc BONE DELIVERY CONJUGATES AND PROCEDURE TO USE IT FOR TARGETING PROTEINS AGAINST BONE
WO2005113606A2 (en) 2004-05-13 2005-12-01 Eli Lilly And Company Fgf-21 fusion proteins
EP1758575A1 (en) 2004-06-11 2007-03-07 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
WO2006037811A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted exendin-4 compounds
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
US20090214534A1 (en) * 2004-12-02 2009-08-27 Steve Holmes Bispecific Domain Antibodies Targeting Serum Albumin And GLP-1 Or PYY
JP2008525452A (ja) * 2004-12-22 2008-07-17 イーライ リリー アンド カンパニー Ｇｌｐ−１類似体融合蛋白質製剤
KR20070090036A (ko) * 2004-12-22 2007-09-04 센토코 인코포레이티드 Ｇｌｐ-1 작용제, 조성물, 방법 및 용도
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
KR20070120112A (ko) * 2005-03-18 2007-12-21 노보 노르디스크 에이/에스 연장형 ｇｌｐ-1 화합물
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP1871811A4 (en) * 2005-03-28 2009-07-22 Centocor Inc MIMETICORPS OF HUMAN GLP-1, COMPOSITIONS, METHODS AND USES
WO2006121810A2 (en) * 2005-05-06 2006-11-16 Providence Health System Trimeric ox40-immunoglobulin fusion protein and methods of use
DE602006017202D1 (de) * 2005-05-13 2010-11-11 Lilly Co Eli Pegylierte glp-1-verbindungen
US8658174B2 (en) 2005-07-27 2014-02-25 Qinghua Wang GLP/1/exendin 4 IgG Fc fusion constructs for treatment of diabetes
KR20080050576A (ko) * 2005-07-29 2008-06-09 앰프로틴 코포레이션 키메릭 치료제
CN101277722A (zh) * 2005-08-06 2008-10-01 王庆华 用于预防和治疗ⅰ型糖尿病的组合物及方法
CA2617649A1 (en) * 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
CN101296942A (zh) * 2005-08-11 2008-10-29 安米林药品公司 具有可选择特性的杂合多肽
RS51319B (sr) * 2005-09-22 2010-12-31 Biocompatibles Uk Limited GLP-l (GLUKAGON-LIKE PEPTID-l) FUZIONI POLIPEPTIDI SA POVEĆANOM OTPORNOSTI NA PEPTIDAZE
US20090286724A1 (en) * 2005-10-26 2009-11-19 Chugai Seiyaku Kabushiki Kaisha Aggregable glp-1 analogue and sustained-release pharmaceutical composition
JP2009514900A (ja) * 2005-11-04 2009-04-09 スミスクライン・ビーチャム・コーポレイション 血糖降下剤の投与方法
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
CN1962695B (zh) * 2005-11-09 2011-08-31 浙江德清安平生物制药有限公司 类胰高血素肽-1融合蛋白及其制备和用途
US20080280328A1 (en) * 2005-11-18 2008-11-13 Novozymes A/S Glucoamylase Variants
JPWO2007063907A1 (ja) * 2005-11-30 2009-05-07 塩野義製薬株式会社 ペプチド糖鎖付加体およびそれを有効成分とする医薬
EP2364735A3 (en) 2005-12-16 2012-04-11 Nektar Therapeutics Branched PEG conjugates of GLP-1
WO2007073486A2 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
PL2463305T3 (pl) * 2006-01-12 2017-02-28 Alexion Pharmaceuticals, Inc. Przeciwciała przeciw OX-2/CD200 i ich zastosowania
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US7553940B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting EPO polypeptides and derivatives thereof and methods thereof
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
CN101003574B (zh) * 2006-02-21 2010-12-15 大连帝恩生物工程有限公司 长效降血糖肽的重组表达及其在糖尿病治疗药物中的应用
US8288339B2 (en) 2006-04-20 2012-10-16 Amgen Inc. GLP-1 compounds
ATE444741T1 (de) 2006-05-10 2009-10-15 Biocompatibles Uk Ltd Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
CA2652907A1 (en) 2006-05-26 2007-12-06 Amylin Pharmaceuticals, Inc. Compositions and methods for treatment of diabetes
EP2474318A1 (en) 2006-06-07 2012-07-11 Human Genome Sciences, Inc. Albumin fusion proteins
EP2049567A2 (en) * 2006-07-18 2009-04-22 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
DK2046826T3 (da) 2006-07-24 2011-10-24 Biorexis Pharmaceutical Corp Exendin-fusionsproteiner
JP4958975B2 (ja) * 2006-08-31 2012-06-20 エフ．ホフマン−ラ ロシュ アーゲー インスリン様増殖因子ｉの製造方法
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
MX2009002547A (es) * 2006-09-06 2009-06-19 Phasebio Pharmaceuticals Inc Composiciones terapeuticas de peptido de fusion.
PE20080840A1 (es) * 2006-09-13 2008-08-27 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion
TWI428346B (zh) * 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
AU2011254001B2 (en) * 2007-01-05 2012-08-02 Covx Technologies Ireland Limited Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP1972349A1 (en) * 2007-03-21 2008-09-24 Biocompatibles UK Limited GLP-1 fusion peptides conjugated to polymer(s), their production and use
EP1975176A1 (en) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Novel glp-1 fusion peptides, their production and use
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
PT2157967E (pt) 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Formulações de suspensões de péptidos insulinotrópicos e suas utilizações
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
JP2010534242A (ja) 2007-07-25 2010-11-04 アレクシオン ファーマシューティカルズ， インコーポレイテッド 自己免疫疾患を治療するための方法および組成物
US20110034373A1 (en) 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
CN101868476B (zh) 2007-09-05 2015-02-25 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途
EP2190873B1 (en) * 2007-09-05 2015-07-22 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
ES2532116T3 (es) 2007-09-05 2015-03-24 Novo Nordisk A/S Péptidos derivados con A-B-C-D y sus usos terapéuticos
US9139634B2 (en) 2007-09-21 2015-09-22 The Regents Of The University Of California Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities
WO2009059278A1 (en) * 2007-11-02 2009-05-07 Centocor, Inc. Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses
EA018471B1 (ru) * 2008-03-31 2013-08-30 Глаксо Груп Лимитед Слитые конструкции и конъюгаты лекарственного средства
BRPI0911266A2 (pt) * 2008-04-03 2015-09-29 Hoffmann La Roche ensaio de fator de crescimento similar à insulina peguilado
CN101328221B (zh) * 2008-04-14 2011-03-23 中国药科大学 一种降糖多肽融合蛋白及其衍生物的结构及用途
CA2726894A1 (en) 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
BRPI0916326A2 (pt) 2008-07-23 2020-08-25 Hanmi Holdings Co., Ltd. complexo polipeptídico compreendendo polímero não-peptidil com três extremidades funcionais
CA2733200A1 (en) * 2008-08-06 2010-02-11 Novo Nordisk Health Care Ag Conjugated proteins with prolonged in vivo efficacy
US20100075897A1 (en) * 2008-09-23 2010-03-25 Jinan University Method for sustainedly releasing bioactive peptides and application thereof
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
BRPI0922689A2 (pt) 2008-12-05 2018-11-06 Angiochem Inc. conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos
EP2364326B1 (en) 2008-12-05 2018-07-04 Glaxo Group Limited Methods for selecting protease resistant polypeptides
HUE031900T2 (en) 2008-12-10 2017-08-28 Glaxosmithkline Llc Pharmaceutical compositions containing Albiglutide
ES2542202T3 (es) 2009-01-22 2015-08-03 Novo Nordisk Health Care Ag Compuestos de hormonas de crecimiento estables
ES2630253T3 (es) 2009-02-11 2017-08-18 Albumedix A/S Variantes de albúmina y conjugados
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
AU2010227552B2 (en) 2009-03-27 2015-02-26 Glaxo Group Limited Drug fusions and conjugates
EP2421562B1 (en) 2009-04-20 2019-03-13 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
AU2010268726A1 (en) 2009-07-02 2012-01-19 Angiochem Inc. Multimeric peptide conjugates and uses thereof
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
US9029505B2 (en) 2009-08-14 2015-05-12 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
CN101993496B (zh) * 2009-08-20 2013-06-05 重庆富进生物医药有限公司 双重调节血糖血脂融合蛋白及其制法和用途
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
MX2012003939A (es) 2009-09-30 2012-07-30 Glaxo Group Ltd Fusiones y conjugados de farmaco.
WO2011043530A1 (ko) * 2009-10-09 2011-04-14 (주)알테오젠 Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물
WO2011050052A2 (en) * 2009-10-20 2011-04-28 Georgia State University Research Foundation, Inc. Protein agent for diabetes treatment and beta cell imaging
WO2011051489A2 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
CN102070717B (zh) * 2009-11-19 2013-04-10 东莞太力生物工程有限公司 融合蛋白及其制备方法、编码该蛋白的dna序列、表达载体、宿主细胞、含有该蛋白的药物组合物
EP2826489A1 (en) 2009-12-08 2015-01-21 Teva Pharmaceutical Industries, Ltd. BChE albumin fusions for the treatment of cocaine abuse
MX345736B (es) 2010-01-22 2017-02-14 Novo Nordisk Healthcare Ag Hormonas de crecimiento con eficacia in vivo prolongada.
WO2011089250A2 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Stable growth hormone compounds
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
CN101875700B (zh) * 2010-04-09 2012-09-26 无锡和邦生物科技有限公司 一种增加促胰岛素分泌肽融合蛋白生物活性的方法
US9168288B2 (en) 2010-04-09 2015-10-27 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
WO2011124718A1 (en) 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
KR20130093470A (ko) 2010-04-30 2013-08-22 가부시키가이샤산와카가쿠켄큐쇼 생리활성 물질 등의 생체 내 안정성 향상을 위한 펩티드 및 생체 내 안정성이 향상된 생리활성 물질
EP2566502A4 (en) 2010-05-04 2013-10-09 Glaxosmithkline Llc METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
WO2011153642A1 (en) * 2010-06-10 2011-12-15 Angiochem Inc. Leptin and leptin analog conjugates and fusion proteins and uses thereof
CN101891823B (zh) * 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
US9234023B2 (en) * 2010-06-24 2016-01-12 Biousian Biosystems, Inc. Glucagon-like peptide-1 glycopeptides
AU2011274229A1 (en) 2010-07-02 2013-01-10 Angiochem Inc. Short and D-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
CN102311501A (zh) * 2010-07-08 2012-01-11 天津药物研究院 含有glp-1或其类似物的融合蛋白、制备方法及其应用
CN101906158B (zh) * 2010-07-14 2013-10-23 中国药科大学 一种聚乙二醇化降糖多肽及其制法和用途
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CN102532323B (zh) * 2010-12-09 2014-07-23 天津药物研究院 一种多肽复合物、药物组合物、其制备方法和应用
DK2651398T3 (en) 2010-12-16 2018-03-12 Novo Nordisk As Solid compositions comprising a GLP-1 agonist and a salt of N- (8- (2-hydroxybenzyl) amino) caprylic acid
CN102533655A (zh) * 2010-12-21 2012-07-04 青岛黄海制药有限责任公司 高效表达人源重组蛋白GLP1/Fc的CHO-S细胞株及其建立方法
AU2011350066A1 (en) 2010-12-27 2013-07-11 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
WO2012097333A2 (en) 2011-01-14 2012-07-19 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
KR101969526B1 (ko) 2011-02-28 2019-04-17 고쿠리츠켄큐카이하츠호진 고쿠리츠쥰칸키뵤 겐큐센터 악성 종양 전이 억제용 의약
EP2681245B1 (en) 2011-03-03 2018-05-09 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
CN103619175B (zh) 2011-04-12 2016-08-17 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
EP2717902B1 (en) 2011-06-06 2018-01-24 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
ES2746052T3 (es) 2011-06-28 2020-03-04 Inhibrx Lp Polipéptidos de fusión de serpina y métodos de uso de los mismos
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
CA2839622A1 (en) * 2011-06-28 2013-01-03 Inhibrx Llc Wap domain fusion polypeptides and methods of use thereof
RU2014103288A (ru) 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
EP2729494A1 (en) 2011-07-08 2014-05-14 Bayer Intellectual Property GmbH Fusion proteins releasing relaxin and uses thereof
WO2013027680A1 (ja) 2011-08-19 2013-02-28 独立行政法人国立循環器病研究センター ナトリウム利尿ペプチド受容体gc-aアゴニスト及びgc-bアゴニストを組み合わせてなる悪性腫瘍の増悪防止用医薬
JP6118251B2 (ja) * 2011-08-25 2017-04-19 株式会社Ｌｓｉメディエンス グルカゴン様ペプチド−１の測定方法及びそれに使用するキット
ES2626013T3 (es) 2011-09-06 2017-07-21 Novo Nordisk A/S Derivados de GLP-1
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
EP2788027A2 (en) 2011-12-09 2014-10-15 Novo Nordisk A/S Glp-1 agonists
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
MX2014009129A (es) 2012-01-26 2014-11-21 Amgen Inc Polipeptidos de factor 15 de diferenciacion de crecimiento (gdf-15).
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
BR112014018679A2 (pt) 2012-03-16 2017-07-04 Novozymes Biopharma Dk As variantes de albumina
RS57727B1 (sr) 2012-03-22 2018-12-31 Novo Nordisk As Kompozicije glp-1 peptida i njihovo dobijanje
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
AU2013250711A1 (en) 2012-04-19 2014-11-27 Opko Biologics Ltd. Long-acting oxyntomodulin variants and methods of producing same
CN104411321A (zh) 2012-05-16 2015-03-11 葛兰素集团有限公司 用于口服施用的加载有多肽的聚(辛基氰基丙烯酸酯)纳米颗粒
KR102434075B1 (ko) 2012-05-17 2022-08-19 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
US9745359B2 (en) * 2012-05-18 2017-08-29 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
SI2859015T1 (sl) 2012-06-08 2018-12-31 Alkermes Pharma Ireland Limited Ligandi, modificirani s cirkularno permutacijo, kot agonisti in antagonisti
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
JP6498601B2 (ja) 2012-07-13 2019-04-10 ザイムワークス，インコーポレイテッド 多価ヘテロ多量体足場設計および構築物
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR094821A1 (es) * 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP6487328B2 (ja) 2012-11-08 2019-03-20 アルブミディクス リミティド アルブミン変異体
SG11201503879QA (en) 2012-11-20 2015-06-29 Opko Biolog Ltd Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
BR112015013809A2 (pt) 2012-12-21 2017-11-14 Sanofi Sa derivados de exendina-4 como agonistas duplos de glp1/gip ou trigonais de glp1/gip/lucagon, seu uso e composição farmacêutica
US9409662B2 (en) 2013-01-15 2016-08-09 Teva Pharmaceutical Industries, Ltd. Formulations of albu-BChE, preparation and uses thereof
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
WO2014194100A1 (en) 2013-05-29 2014-12-04 The Regents Of The University Of California Anti-cspg4 fusions with interferon for the treatment of malignancy
CN104277112B (zh) * 2013-07-04 2018-01-26 嘉和生物药业有限公司 长效降血糖融合蛋白
NZ717030A (en) 2013-07-31 2022-04-29 Amgen Inc Growth differentiation factor 15 (gdf-15) constructs
CN103408669B (zh) * 2013-08-01 2016-01-20 江苏泰康生物医药有限公司 Glp-1类似物融合蛋白，及其制备方法和用途
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
EP3033355A1 (en) * 2013-08-16 2016-06-22 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
CA2926087C (en) 2013-10-10 2023-03-14 Beth Israel Deaconess Medical Center, Inc. Tm4sf1 binding proteins and methods of using same
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
BR112016009617A2 (pt) * 2013-12-10 2017-09-19 Hoffmann La Roche Uso de um conjugado de um domínio de ligação e método para distribuição direcionada de um polipeptídeo
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
CN117065044A (zh) * 2014-03-31 2023-11-17 韩美药品株式会社 通过使用免疫球蛋白Fc片段连接改善蛋白质和肽的溶解度的方法
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
WO2015165480A1 (en) 2014-04-30 2015-11-05 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
NO2776305T3 (sl) 2014-04-23 2018-01-27
WO2015172046A1 (en) 2014-05-08 2015-11-12 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
CN104558198A (zh) * 2014-07-25 2015-04-29 成都贝爱特生物科技有限公司 GLP-1类似物和amylin类似物的融合蛋白制备及其用途
CN104257696B (zh) * 2014-09-04 2017-08-25 西安国誉生物科技有限公司 一种降糖稳糖酵母菌粉及其制备方法和应用
EP3530671A3 (en) 2014-09-05 2019-11-13 University of Copenhagen Gip peptide analogues
US9988430B2 (en) 2014-10-10 2018-06-05 Novo Nordisk A/S Stable GLP-1 based GLP-1/glucagon receptor co-agonists
CN104327187B (zh) * 2014-10-11 2018-06-08 上海兴迪金生物技术有限公司 一种重组人GLP-1-Fc融合蛋白
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
EP3215539A4 (en) * 2014-11-06 2018-05-23 Children's Research Institute, Children's National Immunotherapeutics for cancer and autoimmune diseases
MX2017007392A (es) 2014-12-05 2019-01-24 Alexion Pharma Inc Tratamiento de convulsiones con fosfatasa alcalina recombinante.
CN107108718B (zh) * 2014-12-08 2022-07-22 北京强新生物科技有限公司 可溶性通用的增强adcc的合成融合基因和融合肽的技术及其应用
WO2016118577A1 (en) * 2015-01-22 2016-07-28 Medimmune, Llc Thymosin-beta-four fusion proteins
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
ES2822598T3 (es) 2015-02-09 2021-05-04 Phasebio Pharmaceuticals Inc Métodos y composiciones para tratar enfermedades y trastornos musculares
KR102568272B1 (ko) 2015-02-11 2023-08-21 지맥스 바이오팜 엘엘씨 Ｇｌｐ-1ｒ 항체 융합 단백질의 안정한 약제학적 용액 제형
WO2016161244A2 (en) * 2015-04-01 2016-10-06 The Scripps Research Institute Methods and compositions related to gpcr agonist polypeptides
UA126270C2 (uk) 2015-04-10 2022-09-14 Емджен Інк. Мутеїни інтерлейкіну-2 для росту регуляторних t-клітин
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
JP6823055B2 (ja) 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド 軟髄膜癌腫症の治療方法
KR102662956B1 (ko) 2015-06-19 2024-05-03 옵코 바이오로직스 리미티드 장기-작용성 응고 인자 및 그의 제조 방법
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
CN108137674B (zh) 2015-08-20 2022-12-06 阿尔布梅迪克斯医疗有限公司 白蛋白变体和缀合物
CA2996716A1 (en) 2015-09-04 2017-03-09 The California Institute For Biomedical Research Insulin immunoglobulin fusion proteins
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
CN105367664B (zh) * 2015-11-04 2019-09-20 成都贝爱特生物科技有限公司 激活GLP-1受体和Amylin受体双功能作用的融合蛋白制备及其用途
JP2018538271A (ja) * 2015-11-16 2018-12-27 ユビプロテイン， コーポレーションＵｂｉｐｒｏｔｅｉｎ， Ｃｏｒｐ． タンパク質の半減期延長方法
PT3380495T (pt) 2015-11-24 2021-08-19 Transfert Plus Sec Compostos peptídicos e conjugados peptídicos para o tratamento de cancro através de quimioterapia mediada por recetores
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
JP2019513711A (ja) 2016-04-01 2019-05-30 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
WO2017189432A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
AU2017296352A1 (en) 2016-07-11 2019-02-21 Opko Biologics Ltd. Long-acting coagulation factor VII and methods of producing same
CN106046176B (zh) * 2016-08-16 2019-09-10 中国药科大学 一种高活性长效降糖融合蛋白及其制备方法与医药用途
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
WO2018045872A1 (zh) * 2016-09-06 2018-03-15 中国药科大学 一种多肽及其用途
CN109200273B (zh) * 2017-07-04 2021-02-19 中国药科大学 一种多肽用于制备预防或治疗脂肪肝病药物的用途
CN106279400A (zh) * 2016-09-06 2017-01-04 中国药科大学 P8降糖肽的设计及其用途
CA3045134A1 (en) * 2016-12-14 2018-06-21 Ligandal, Inc. Compositions and methods for nucleic acid and/or protein payload delivery
CN106519016A (zh) * 2016-12-20 2017-03-22 中国药科大学 降糖调脂肽——Progly肽的设计及其用途
CN107033234B (zh) * 2017-01-03 2018-06-26 北京凯因科技股份有限公司 酰化的glp-1衍生物
JP2020505029A (ja) 2017-01-25 2020-02-20 メディミューン，エルエルシー リラキシン融合ポリペプチドおよびその使用
KR20190129058A (ko) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
CN108727486A (zh) * 2017-04-24 2018-11-02 舒泰神（北京）生物制药股份有限公司 长效神经生长因子、制备方法及其组合物
CN110945016A (zh) 2017-05-24 2020-03-31 特拉斯福特普拉斯公司 用于治疗炎性疾病的肽化合物、缀合化合物及其用途
AU2018276434B2 (en) 2017-05-31 2021-12-16 University Of Copenhagen Long-acting GIP peptide analogues
SG11202000940XA (en) 2017-08-24 2020-02-27 Novo Nordisk As Glp-1 compositions and uses thereof
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
EP3713593A2 (en) 2017-11-21 2020-09-30 Eli Lilly and Company Methods of using and compositions containing dulaglutide
CN109836504B (zh) * 2017-11-24 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
CN116143939A (zh) * 2017-11-24 2023-05-23 浙江道尔生物科技有限公司 一种治疗代谢疾病的多重活性蛋白
CN111518770B (zh) 2017-12-19 2023-01-06 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
CN110028587B (zh) * 2018-01-11 2021-10-08 安源医药科技（上海）有限公司 用于调节血糖和脂质的增效型双功能蛋白
WO2019140021A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
CN110092835A (zh) * 2018-01-30 2019-08-06 上海惠盾生物技术有限公司 一种glp-1类似物-col3a1融合蛋白
PE20210453A1 (es) 2018-02-02 2021-03-08 Novo Nordisk As Composiciones solidas que comprenden un agonista de glp-1, una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
SG11202009467YA (en) 2018-04-05 2020-10-29 Sun Pharmaceutical Ind Ltd Novel glp-1 analogues
JP7058670B2 (ja) 2018-04-09 2022-04-22 アムジエン・インコーポレーテツド 増殖分化因子１５融合タンパク質
WO2019200594A1 (zh) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
CN110964116A (zh) * 2018-09-26 2020-04-07 北京辅仁瑞辉生物医药研究院有限公司 GLP1-Fc融合蛋白及其缀合物
CN113226351A (zh) * 2018-10-22 2021-08-06 詹森药业有限公司 胰高血糖素样肽1(glp1)-生长分化因子15(gdf15)融合蛋白及其用途
CN112912099A (zh) * 2018-10-24 2021-06-04 夏尔-Nps医药品有限公司 Glp-2融合多肽和用于治疗和预防胃肠病症的用途
WO2020115048A1 (en) 2018-12-03 2020-06-11 Antag Therapeutics Aps Modified gip peptide analogues
WO2020118843A1 (zh) * 2018-12-12 2020-06-18 四川利通科创生物医药科技有限公司 一种glp-1突变体及其制备方法和用途
CN112996811B (zh) 2018-12-21 2022-11-22 江苏恒瑞医药股份有限公司 双特异性蛋白
CA3177693A1 (en) 2019-04-05 2020-10-05 Eli Lilly And Company Therapeutic uses of dulaglutide
CN110151980B (zh) * 2019-06-30 2022-12-09 中国药科大学 Glp-1受体激动剂融合蛋白在制备预防或治疗高血脂药物中的应用
CN114761412B (zh) 2019-11-25 2024-10-11 阿尔克姆斯有限公司 取代的大环化合物和相关治疗方法
KR20220143036A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 약학적 제형
JPWO2021167107A1 (sl) 2020-02-22 2021-08-26
US12122817B2 (en) * 2020-09-22 2024-10-22 Serpentide Inc. Long-lasting GLP1 analogue drug for type-2 diabetes
JP2023545684A (ja) * 2020-09-30 2023-10-31 ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド ポリペプチドコンジュゲートおよび使用の方法
KR20230145120A (ko) 2021-02-12 2023-10-17 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제 폴리펩타이드 및 이의 사용 방법
JPWO2022202816A1 (sl) 2021-03-22 2022-09-29
TW202305012A (zh) 2021-03-22 2023-02-01 日商肽夢想股份有限公司 c-Met 蛋白質結合肽複合物
CN113150172B (zh) * 2021-04-28 2023-09-22 中国药科大学 Glp-1r/gipr双靶点激动剂融合蛋白及其制备方法与应用
IL309196A (en) 2021-06-18 2024-02-01 Peptidream Inc GHR-binding peptide and composition containing it
TW202321274A (zh) 2021-08-19 2023-06-01 日商Ｊｃｒ製藥股份有限公司 人類運鐵蛋白受體結合肽
JPWO2023026994A1 (sl) 2021-08-21 2023-03-02
US20240366775A1 (en) 2021-08-24 2024-11-07 Peptidream Inc. Human transferrin receptor binding antibody-peptide conjugate
KR20240082377A (ko) 2021-09-30 2024-06-10 페프티드림 아이엔씨. 펩티드
CN113801853B (zh) * 2021-11-19 2022-03-15 山东兴瑞生物科技有限公司 Exendin-4融合基因修饰的MSC及其应用
CN117241821B (zh) * 2022-03-25 2024-04-09 北京质肽生物医药科技有限公司 多肽缀合物的药物组合物及其使用方法
CN116848243B (zh) * 2022-03-30 2024-03-19 北京质肽生物医药科技有限公司 多肽缀合物的液体药物组合物和其使用方法
AU2023246202A1 (en) 2022-03-30 2024-10-17 Peptidream Inc Peptide complex having trkb binding activity
CN114774496B (zh) * 2022-06-21 2022-10-04 北京惠之衡生物科技有限公司 一种高密度发酵制备glp-1类似物的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5766883A (en) * 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
FR2650598B1 (fr) * 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
CN1149887A (zh) * 1994-04-22 1997-05-14 科里克萨有限公司 刺激和增强保护性免疫反应和il-12产生的化合物和方法
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
PE99498A1 (es) 1996-07-26 1999-01-21 Novartis Ag Polipeptidos de fusion
JP2001501593A (ja) 1996-08-08 2001-02-06 アミリン・ファーマシューティカルズ，インコーポレイテッド 胃腸運動を調節するための方法
CA2468374C (en) * 1996-08-30 2010-12-21 Novo-Nordisk A/S Glp-1 derivatives
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6190909B1 (en) * 1997-04-17 2001-02-20 Millennium Pharmaceuticals, Inc. TH2-specific gene
EP0887061A1 (en) * 1997-06-28 1998-12-30 The Procter & Gamble Company Faecal collector
ES2293688T5 (es) 1997-08-08 2011-05-04 Amylin Pharmaceuticals, Inc. Nuevos compuestos análogos de la exendina.
ATE383867T1 (de) 1997-11-14 2008-02-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
MXPA00004670A (es) 1997-11-14 2003-07-14 Amylin Pharmaceuticals Inc Compuestos agonistas de exendina novedosos.
WO1999040788A1 (en) 1998-02-13 1999-08-19 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
DE69942306D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
EP1061946B1 (en) * 1998-02-27 2004-04-28 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1062240B1 (en) * 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
JP4087563B2 (ja) * 1998-06-15 2008-05-21 ジーティーシー バイオセラピューティックス インコーポレイテッド エリスロポエチン類似体−ヒト血清アルブミン融合物
EP2154535A1 (en) * 1998-12-10 2010-02-17 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
WO2000069911A1 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting insulinotropic peptides
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
JP2003530852A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins

Also Published As

Publication number Publication date
EA005584B1 (ru) 2005-04-28
IL155812A (en) 2009-09-22
JP2011006447A (ja) 2011-01-13
WO2002046227A3 (en) 2003-04-24
PL209550B1 (pl) 2011-09-30
IL184429A0 (en) 2007-10-31
DE60135581D1 (de) 2008-10-09
EP1724284A2 (en) 2006-11-22
HUP0302529A2 (hu) 2003-10-28
HRP20030455A2 (en) 2004-08-31
UA81897C2 (uk) 2008-02-25
EP1355942B1 (en) 2008-08-27
ES2328510T3 (es) 2009-11-13
CZ308214B6 (cs) 2020-03-04
HU230603B1 (hu) 2017-03-28
DE60139430D1 (de) 2009-09-10
EP1355942A2 (en) 2003-10-29
ATE437891T1 (de) 2009-08-15
CA2434237C (en) 2012-05-15
PT1724284E (pt) 2009-09-30
EP1724284B1 (en) 2009-07-29
EP1724284A3 (en) 2007-04-18
NO20032565D0 (no) 2003-06-05
JP2004528014A (ja) 2004-09-16
KR20080085082A (ko) 2008-09-22
CA2716959A1 (en) 2002-06-13
NO20032565L (no) 2003-08-01
ECSP064643A (es) 2009-07-25
DK1355942T3 (da) 2008-11-17
CA2434237A1 (en) 2002-06-13
AU2689702A (en) 2002-06-18
UA93662C2 (uk) 2011-03-10
CY1109377T1 (el) 2014-07-02
BR0116024A (pt) 2005-12-13
HUP1300326A2 (en) 2003-10-28
WO2002046227A2 (en) 2002-06-13
PL366208A1 (en) 2005-01-24
NO20111369L (no) 2003-08-01
DK1724284T3 (da) 2009-11-02
ES2311560T3 (es) 2009-02-16
AU2002226897B2 (en) 2007-10-25
CN1483041A (zh) 2004-03-17
HU229218B1 (en) 2013-09-30
SK288088B6 (sk) 2013-06-03
US20040053370A1 (en) 2004-03-18
NO331273B1 (no) 2011-11-14
PL393178A1 (pl) 2011-02-14
US7271149B2 (en) 2007-09-18
CY1108485T1 (el) 2014-04-09
KR20040038901A (ko) 2004-05-08
IL155812A0 (en) 2003-12-23
CZ306180B6 (cs) 2016-09-14
ZA200303642B (en) 2004-08-12
CZ2014740A3 (sl) 2006-04-12
KR100942864B1 (ko) 2010-02-17
SI1724284T1 (sl) 2009-12-31
ATE406384T1 (de) 2008-09-15
HUP0302529A3 (en) 2009-03-30
NO332221B1 (no) 2012-07-30
EA200300644A1 (ru) 2003-12-25
MXPA03005036A (es) 2003-09-05
NZ525577A (en) 2005-05-27
NO20101602L (no) 2003-08-01
HK1061411A1 (en) 2004-09-17
PT1355942E (pt) 2008-11-21
SK6702003A3 (en) 2004-08-03
SK288342B6 (en) 2016-03-01
CZ20031602A3 (cs) 2006-04-12
IL184429A (en) 2010-04-15
CN101712722A (zh) 2010-05-26

Similar Documents

Publication Publication Date Title
AU2689702A (en) Glp-1 fusion proteins
WO2003058203A3 (en) Extended glucagon-like peptide-1 analogs
EP2022505A3 (en) GLP-1, exendin-4, peptide analogs and uses thereof
AU2002322403A1 (en) Glucagon-like peptide-1 analogs
HUP0204281A3 (en) Process for sulubilizing glucagon-like peptide 1 (glp-1) compounds
WO2001098331A3 (en) Glucagon-like peptide-1 analogs
EP1373301A4 (en) WEAKNESS OF IMMUNOGENICITY OF FUSION PROTEINS
SI1095140T1 (sl) Nevrotrofični dejavniki
HK1120556A1 (en) Neurotrophic factors
EP1264603B8 (en) Use of L-polynucleotides for in vivo imaging
WO2001080871A3 (de) Anwendung von guanylat-zyklase-c (gc-c) agonisten als insulinotrope faktoren zur behandlung von diabetes mellitus typ 2
MXPA01011719A (es) Una composicion de somatotropina con inyectabilidad mejorada.
UA88862C2 (en) Glucagon-like peptide-1 analogs